Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 87 clinical trials
Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

purpose of this clinical study is to produce the CD19[cluster of differentiation antigen 19] CAR-T (SNUH-CD19-CAR-T) at the investigational site and to evaluate safety and efficacy of SNUH-CD19-CAR-T in

  • 0 views
  • 14 Mar, 2022
  • 1 location
Treatment of POEMS Syndrome With Daratumumab

This trial investigates the use of Daratumumab (DARA), an antibody directed at the human cluster of differentiation 38 (CD38) molecule, for the treatment of patients with Polyneuropathy

  • 4 views
  • 10 Aug, 2022
  • 1 location
CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Refractory and relapsed (R/R) acute lymphoblastic leukemia (ALL) patients with active disease always have a dismal outcome. Chimeric antigen receptor (CAR) T-cell therapy targeting to Cluster of

  • 0 views
  • 03 Feb, 2022
  • 1 location
Comparison Between Systemic Steroids Topical Steroids or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo

The study to compare the outcomes of mini punch grafting in patients with resistant stable non-segmental vitiligo already on narrowband ultraviolet B and receiving either no additional medication , systemic mini pulse (high and low dose) steroids, topical superpotent steroids once every other day , or daily tacrolimus ointment .in …

  • 23 views
  • 28 Feb, 2021
  • 1 location
Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men (GoGoVax)

+ [GBM+], either HIV-negative and taking pre-exposure prophylaxis [PrEP], or HIV-positive with undetectable viral load <200copies/ml and a cluster of differentiation 4 [CD4] count >350 cells/cmm

  • 6 views
  • 26 Apr, 2022
  • 2 locations
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma (LINKER-MM1)

prior lines of therapy or who are triple-refractory (defined as refractory to a(n) proteasome inhibitor (PI), immunomodulatory imide (IMiD) drug (s), and anti-cluster of differentiation 38 (anti-CD38

immunotherapeutic agent
immunomodulatory imide drug
lenalidomide
proteasome inhibitor
refractory multiple myeloma
  • 25 views
  • 23 Jul, 2022
  • 24 locations
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.

measurable disease
proteasome inhibitor
daratumumab
serum immunoglobulin a
immunomodulatory imide drug
  • 114 views
  • 27 Jul, 2022
  • 22 locations
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3)

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

platelet count
TACE
liver transplant
neutrophil count
nivolumab
  • 19 views
  • 27 Feb, 2022
  • 1 location
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the …

  • 0 views
  • 13 Apr, 2022
  • 1 location
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.

targeted therapy
lymphoma
taxane
ROS1
sarcoma
  • 0 views
  • 03 May, 2022
  • 16 locations